Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-004 in HIV infection
NCT01069809Phase 2Completed
- Sponsor
- Argos Therapeutics
- Start
- Jul 2010
- Primary completion
- Aug 2014
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing AGS-004 with Placebo (2 arms). Primary endpoint: New HIV Viral Load setpoint after a 12 week Analytical Treatment Interruption. Started Jul 2010; status: completed.
02
Drugs
rocapuldencel-T
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01069809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01069809.